Novel approaches to the treatment of chronic graft-versus-host disease.
Chronic graft-versus-host disease (cGvHD) continues to be the major problem in long-term survivors of allogeneic haematopoietic stem cell transplants and is the principal cause of morbidity and non-relapse mortality. Over the past twenty years, diagnosis, prophylaxis and treatment of cGvHD have slowly evolved. An effective therapy for cGvHD is designed to prevent complications through targeting the disease mechanisms. None of the present therapies for cGvHD are successful in the majority of patients. Conventional drugs in different combinations can control the disease in approximately 50% of patients. Attempts to improve survival have led to evaluation of several alternative approaches in the treatment of refractory cGvHD with varying degrees of success. Clinical trials are needed to establish the role of these new approaches in the treatment of cGvHD as first line or salvage therapy without causing significant side effects. This review summarises the currently available knowledge on conventional and new treatment approaches for cGvHD.
Gaziev
D
D
Unità Operativa di Ematologia e Centro Trapianti Midollo Osseo de Muraglia, Azienda Ospedaliera S. Salvatore di Pesaro, Italy.
Lucarelli
G
G
D002908:Chronic Disease; D006086:Graft vs Host Disease / Q000628:therapy*; D006801:Humans; D008221:Lymphoid Tissue / Q000528:radiation effects; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D010778:Photochemotherapy; D016559:Tacrolimus / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use
D013792:Thalidomide; D009173:Mycophenolic Acid; D016559:Tacrolimus